Mr Mrs Miss Ms Dr Other

Dr
Benoit
Liénard

Partner & Patent Attorney

Paris Office Rennes Office

Life sciences

Telephone. +33 (0)1 59 04 05 69
Email. blienard@hgf.com
UPC Representative
Our team of specialist European patent litigators, oppositions specialists and patent attorneys bring together an extensive depth of legal and technical knowledge and are qualified to represent you in the UPC.
Vcard
Linkedin

Experience

With nearly twenty years of experience spanning major IP firms, in-house counsel roles, start-up creation, and firm management, Benoit brings a uniquely holistic perspective to intellectual property. He believes that IP should never stand apart from a company’s commercial reality, it should be a growth engine.

For Benoit, advising clients goes far beyond securing patents. He works side by side with innovators as if he were part of their internal team, ensuring they can fully leverage their intellectual assets at every stage of their journey. From identifying and claiming public subventions, to structuring fundraising with private investors, family offices, venture capital or private equity, to navigating fiscal aspects of IP, Benoit helps clients transform ideas into sustainable businesses.

He also guides companies in building global IP localisation strategies, negotiating licensing or asset sales, and making sure IP decisions directly serve long-term value creation. Whether a start-up, scale-up, or established enterprise, clients know they can rely on Benoit for integrated strategic counsel that bridges IP law, finance, and business development, unlocking the true potential of their science.

Specialisms

Industries

Services

Qualifications

Patent Attorney

Europe
France

LLM

Intellectual Property Law LLM | Brunel University of London

LLM

CEIPI | Strasbourg University

PHD

PhD in Chemical Biology

POSTGRADUATE DIPLOMA OR CERTIFICATE

French Patent Attorney

POSTGRADUATE DIPLOMA OR CERTIFICATE

European Patent Attorney

POSTGRADUATE DIPLOMA OR CERTIFICATE

UPC Representative

Publications

The Antibody Series #2 | Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

View publication online

The Antibody Series #1 | Quality Characteristics (CQAs) in Antibody Claims: When the Test Method Can Remain Outside the Claim

View publication online

Related News

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

The concept of ‘overall impression’ in UK and EU Registered Design Law

 

Read article

The Antibody Series #2 | Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

Introduction Defining an antibody by its binding strength is common practice in patent claims, but it can quickly become a pitfall under Article 84 EPC on clarity. In this second …

Read article

The Antibody Series #1 | Quality Characteristics (CQAs) in Antibody Claims: When the Test Method Can Remain Outside the Claim

Introduction Therapeutic antibodies are at the heart of innovations in biotechnology and healthcare. With increasing regulatory requirements and quality expectations, critical quality attributes (CQAs) are becoming essential in the drafting …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us